CEO Executive AssistantKnowing how pharma CEOs delegate commercial launch operations determines whether a product achieves its potential or stalls in the critical window between regulatory approval and market adoption. Commercial launches in pharma are high-complexity, cross-functional endeavors involving regulatory affairs, medical affairs, market access, commercial operations, supply chain, and investor relations, all converging on a tight timeline. The CEO who tries to personally manage this coordination will become a bottleneck. The CEO who disengages from launch entirely will find that commercial milestones slip, investor expectations are mismanaged, and the Chief Commercial Officer lacks the organizational authority to drive cross-functional decisions at the necessary speed. The delegation model must be precise.
What Demands CEO Visibility in a Commercial Launch
Not every launch decision requires the CEO, but several categories of launch activity are high enough stakes that they require CEO engagement, presence, or sign-off.
Market authorization milestones. The moments when regulatory agencies formally approve a product for marketing are CEO events. The CEO is the public face of the company at approval. The FDA approval announcement, the investor call following approval, the communications to employees and partners, and the first public statements about launch timing all carry the CEO’s voice and authority. These are not activities to delegate. The CEO is also the right person to call key customers, physicians, and institutional partners at the moment of approval, reinforcing the significance of the milestone.
Key payor negotiations. Access to formulary coverage from major payors, including CMS for Medicare and Medicaid products, large commercial insurers, and integrated health systems with their own formularies, is a material driver of launch success. The negotiations with the largest payors may involve rebate commitments, outcomes-based contracting arrangements, or risk-sharing agreements that carry significant financial implications. The CEO should be informed of the negotiating strategy for top-tier payors and involved in any payor relationship where the deal structure is novel, precedent-setting, or materially affects financial guidance. The market access team manages the vast majority of payor interactions; the CEO engages at the strategic inflection points.
Launch readiness reviews. A formal launch readiness review, typically conducted 60 to 90 days before the anticipated approval date, assesses whether the commercial organization is prepared to execute: sales force training completion, distribution partnerships confirmed, payor contracting status, promotional materials approved, and supply chain commitments in place. The CEO should chair or attend this review as a signal to the organization that launch readiness is a company-level priority. This is one occasion where CEO presence has genuine motivational and accountability value beyond simply receiving a report.
Investor and analyst management around launch. Launch is the period of maximum investor scrutiny for a pharma company. Revenue projections, market penetration assumptions, and competitive positioning are all under investor review. The CEO is the primary voice for investor communications around launch milestones and should be closely aligned with the CFO and investor relations function on launch messaging. This does not mean the CEO owns all investor communications, but the CEO must personally understand and confidently communicate launch progress.
What the Chief Commercial Officer and Launch Team Own
The Chief Commercial Officer (CCO) and the launch execution team own the overwhelming majority of the operational work associated with a commercial launch. A well-structured CCO with a competent team should be executing all of the following without routine CEO involvement.
Regional execution plans. National commercial strategy translates into regional execution across sales territories, key accounts, and market segments. Regional directors and their teams own the adaptation of national strategy to local market dynamics. The CCO oversees regional performance through a commercial operations review cadence. The CEO does not need to be involved in regional execution decisions.
Sales force deployment and training. Hiring, deploying, and training the commercial sales force, including medical science liaisons and key account managers, is a CCO function. Field force sizing, territory design, call plan design, and training curriculum are all commercial operations decisions. The CEO trusts that the commercial organization is building the right field force and monitors outcomes, not inputs.
Promotional material development and approval. Regulatory review of promotional materials through the Medical, Legal, and Regulatory (MLR) review process is a joint function of medical affairs, legal, and regulatory, coordinated by the commercial team. The CEO is not in the MLR review process and does not review promotional materials before they are finalized unless there is an exceptional strategic or compliance concern.
Distribution and supply chain coordination. Working with specialty pharmacy partners, wholesalers, and distribution networks to ensure product availability is a commercial operations and supply chain function. The CEO monitors supply security as a strategic risk but does not manage the logistics.
The pharma regulatory delegation framework complements this by addressing how regulatory affairs strategy supports the commercial launch without requiring CEO operational involvement in submission management.
Empowering Market Access Teams
Market access is one of the most consequential functions in a commercial launch, and it is also one of the areas where CEOs most frequently underdelegate, either by remaining too personally involved in payor negotiations or by failing to give the market access team the organizational authority they need to move quickly.
Market access teams, which include HEOR (Health Economics and Outcomes Research) professionals, medical affairs personnel, and pricing and contracting specialists, work within a defined pricing and contracting framework that the CEO and CFO set at the strategic level. Within that framework, the market access team should have full authority to negotiate with payors, execute contracting decisions, and design value demonstration programs.
The CEO’s role is to set the strategic parameters: the pricing floor, the acceptable formulary positioning tradeoffs, the types of outcomes-based arrangements the company is willing to pursue, and the key accounts where CEO-level engagement in the relationship is warranted. With these parameters set, the market access team can execute without requiring CEO sign-off on individual payor agreements.
This empowerment requires two supporting structures. First, a market access decision matrix that specifies which contracting decisions are within the CCO’s authority and which require CEO or board approval. Second, a regular market access briefing in the CEO’s operating rhythm, typically monthly during the launch period, where the market access team reports on formulary wins, contracting status, and key risks.
Structuring Launch Governance Without CEO Bottlenecks
The most common structural failure in pharmaceutical commercial launches is a governance model that routes too many decisions to the CEO or the executive team. When the launch is the company’s primary strategic initiative, there is a natural tendency for senior leadership to want to be closely involved in execution. This tendency, while well-intentioned, slows the launch.
The right governance model is a tiered launch governance structure with clear decision rights at each level.
The launch steering committee meets weekly during the active launch period and is co-chaired by the CCO and CMO (Chief Medical Officer). The CEO is not a standing member of this committee. The steering committee resolves cross-functional conflicts, approves resource adjustments within the launch budget, and monitors launch milestones. The CEO receives a weekly launch dashboard from this committee.
The cross-functional launch team includes commercial operations, medical affairs, market access, regulatory affairs, supply chain, and legal representatives. This team meets weekly to manage operational launch execution. The CEO is not involved in these meetings.
CEO escalation triggers are pre-defined events that bring the CEO into the launch decision process: a significant safety signal requiring public communication, a payor decision that affects financial guidance, a competitive development requiring a strategy change, or a supply constraint that affects launch timing. These escalation triggers should be documented before launch so that the CCO and launch team know exactly when to bring the CEO in.
This governance model gives the commercial organization the speed and authority to execute a launch effectively, while ensuring the CEO is engaged at the strategic inflection points that genuinely require CEO authority.
Managing Competitive Dynamics During Launch
Pharmaceutical markets are rarely uncrowded, and launch dynamics are frequently shaped by competitive product launches, label expansions by existing therapies, and competitive messaging from established market players. Managing competitive response is a real-time activity during launch.
The commercial operations and competitive intelligence team should have a real-time competitive monitoring function, with a protocol for communicating competitive developments to the CCO and CEO. The CCO owns the day-to-day competitive response, including adjusting messaging, shifting resource allocation, or accelerating certain promotional activities. The CEO is informed of significant competitive developments and is involved in strategic decisions, such as whether to accelerate a label expansion application or adjust pricing strategy in response to competitive dynamics.
According to McKinsey analysis of pharmaceutical launch performance, products that achieve first-quartile launch success consistently demonstrate superior cross-functional coordination and clear decision rights, not superior commercial budgets. Governance structure is a more reliable predictor of launch success than launch spend.
The CEO’s Role in Launch Culture and Organizational Energy
One dimension of commercial launch leadership that is genuinely CEO-owned and cannot be delegated is the cultural energy around the launch. Launches are demanding, high-pressure events for the commercial organization. The sales force is being evaluated against ambitious targets. The market access team is navigating complex negotiations. Medical affairs is managing a high volume of physician interactions. Every team is under pressure.
The CEO’s presence, attention, and messaging during this period matter enormously to organizational morale and motivation. This does not mean micromanaging. It means showing up at the national sales meeting, sending a personal message to the field force at the moment of approval, recognizing early wins publicly, and being visibly committed to the launch’s success.
This kind of cultural leadership is a genuine CEO function that no CCO or chief of staff can fully substitute for. It requires authentic CEO engagement, but it is a very different kind of engagement from operational management. The CEO who shows up to motivate and recognize, without jumping into execution decisions, has the right calibration.
The companion framework on pharma clinical delegation addresses how CEOs build similar delegation structures across the clinical development organization, many of which support the evidence base that drives commercial launch success.
Building a Launch-Ready CEO Operating Rhythm
The CEO’s operating rhythm during the launch period needs to accommodate the higher frequency of decisions, communications, and cross-functional demands that a launch creates, without consuming the CEO’s bandwidth for external activities, board management, and investor relations that also intensify during this period.
A practical launch period CEO cadence includes: a weekly 30-minute launch dashboard review with the CCO, a monthly launch steering committee briefing, bi-weekly alignment with the CFO on financial pacing against launch projections, and investor communications coordinated with the IR team. This cadence keeps the CEO informed and strategically engaged without operational immersion.
The CCO should be empowered to escalate to the CEO at any time when a decision requires CEO authority, with the understanding that the escalation threshold is genuinely high. A CCO who escalates routine launch decisions to the CEO is not yet fully empowered. A CEO who expects to be involved in routine decisions has not yet built the delegation muscle. Getting both right takes deliberate investment in the launch governance structure before the launch window opens.
The pharma CEO who builds this structure, trusts the commercial organization to execute within it, and shows up at the strategic and cultural moments that require genuine CEO presence will deliver consistently better launch outcomes than the CEO who tries to manage the launch directly.
Related Reading
For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.